Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

Daewoong Pharmaceutical Co / Equity Bottom-Up

<ul>
 <li>Daewoong's growth is propelled by the successful global expansion of its key products, the botulinum toxin Nabota and the GERD treatment Fexuclue, which are driving strong revenue and margin improvement.</li>
 <li>The company faces significant concentration risk, with its future performance heavily dependent on these two blockbuster drugs, alongside a relatively thin late-stage pipeline.</li>
 <li>Ongoing litigation with Medytox over botulinum toxin strains presents a key uncertainty, while a history of negative free cash flow and limited shareholder returns are notable financial concerns.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  Daewoong's growth is propelled by the successful global expansion of its key products, the botulinum toxin Nabota and the GERD treatment Fexuclue, which are driving strong revenue and margin improvement.
  The company faces significant concentration risk, with its future performance heavily dependent on these two blockbuster drugs, alongside a relatively thin late-stage pipeline.
  Ongoing litigation with Medytox over botulinum toxin strains presents a key uncertainty, while a history of negative free cash flow and limited shareholder returns are notable financial concerns.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Daewoong Pharmaceutical Co (069620 KS) - Aug 2026

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hk-inno-n-corp" target="_blank" data-smartkarma-citation="entities:33522:1" rel="noopener">HK inno.N (195940 KS)</a> reported 1Q26 result, with all key parameters showing improvement compared to year-ago period. Continued strong sales of mainstay prescription drug business remained the key driver.</li>
<li>Significant improvement in profitability, driven by double-digit growth in major prescription drug products, along with strong growth in K-CAB China royalty, is the key highlight of 1Q26 result.</li>
<li>HK inno is expected to maintain growth momentum, with U.S. approval of K-CAB being the next catalyst. The company is strengthening prescription drug business and innovative drug pipeline beyond K-CAB.</li>
</ul>



HK inno.N (195940 KS) reported 1Q26 result, with all key parameters showing improvement compared to year-ago period. Continued strong sales of mainstay prescription drug business remained the key driver.
Significant improvement in profitability, driven by double-digit growth in major prescription drug products, along with strong growth in K-CAB China royalty, is the key highlight of 1Q26 result.
HK inno is expected to maintain growth momentum, with U.S. approval of K-CAB being the next catalyst. The company is strengthening prescription drug business and innovative drug pipeline beyond K-CAB.


HK Inno.N (195940 KS): Modest Show In 1Q26; All Eyes on Maiden US Approval; Strengthening Pipeline

External broker reports(aggregated public sources), Mirae Asset Securities

Mirae Asset Securities

External broker reports(aggregated public sources)

Mirae Asset Securities Co.,Ltd. provides comprehensive wealth management services. The Company offers fixed income securities brokerage, securities dealing, equity underwriting, and other services. Mirae Asset Securities also deals with mergers and acquisitions, foreign currency, and financial derivatives

<ul><li>We retain our target price of W210,000 on Daewoong Pharmaceutical.</li><li>Our valuation represents the sum of the firm’s operating value (W2.5tr) and the value of its stake in HanAll Biopharma (W369.9bn), minus net debt (W455.5bn).</li><li>While we slightly revised up our earnings forecasts following strong 3Q25 results, we kept our target price unchanged due to a reduction in our target multiple (9.3x). </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

We retain our target price of W210,000 on Daewoong Pharmaceutical.Our valuation represents the sum of the firm’s operating value (W2.5tr) and the value of its stake in HanAll Biopharma (W369.9bn), minus net debt (W455.5bn).While we slightly revised up our earnings forecasts following strong 3Q25 results, we kept our target price unchanged due to a reduction in our target multiple (9.3x). Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Daewoong Pharmaceutical (069620 KS/Buy)Compelling Valuation

Thematic (Sector/Industry)

<ul>
<li>CSPC Pharmaceutical’s Phase 3 trial of depression drug candidate HA1406 met pre-specified primary efficacy endpoint. Jiangsu Hengrui Pharmaceuticals received NMPA approval for long-acting basal insulin, sudelidec injection.</li>
<li>Otsuka Holdings secured FDA approval for Simtriyo, a once-daily extended-release capsule for ADHD. Nippon Shinyaku obtained exclusive commercialization rights for Tadekinig alfa in the U.S. for Hyperinflammatory Syndrome.</li>
<li>Pharmaessentia announced topline results from the Phase 1b clinical trial of P1101 (Besremi) and anti-PD1 in Chronic Hepatitis B or D. Cipla secured FDA approval for generic Advair Diskus.</li>
</ul>


CSPC Pharmaceutical’s Phase 3 trial of depression drug candidate HA1406 met pre-specified primary efficacy endpoint. Jiangsu Hengrui Pharmaceuticals received NMPA approval for long-acting basal insulin, sudelidec injection.
Otsuka Holdings secured FDA approval for Simtriyo, a once-daily extended-release capsule for ADHD. Nippon Shinyaku obtained exclusive commercialization rights for Tadekinig alfa in the U.S. for Hyperinflammatory Syndrome.
Pharmaessentia announced topline results from the Phase 1b clinical trial of P1101 (Besremi) and anti-PD1 in Chronic Hepatitis B or D. Cipla secured FDA approval for generic Advair Diskus.


APAC Healthcare Weekly (August 2) – CSPC, Hengrui, Otsuka, Nippon Shinyaku, PharmaEssnetia, Cipla

<ul>
<li>CSPC Pharmaceutical entered drug discovery collaboration with AstraZeneca in a deal worth of $1.7B+. Abbisko Cayman is collaborating with AstraZeneca to jointly develop a novel IO-TKI combination therapy for NSCLC.</li>
<li>Insilico inked AI drug discovery deal with Takeda Pharmaceutical worth up to $600M. Nippon Shinyaku secured exclusive worldwide rights to develop and commercialize EXG-7001 for DMD from Elixirgen Therapeutics.</li>
<li>Otsuka’s Voyxact demonstrated significant stabilization of kidney function, with evidence of improvement over two years in Phase 3 trial. EMA recommended to pull CSL’s Tavneos from sale in the EU.</li>
</ul>


CSPC Pharmaceutical entered drug discovery collaboration with AstraZeneca in a deal worth of $1.7B+. Abbisko Cayman is collaborating with AstraZeneca to jointly develop a novel IO-TKI combination therapy for NSCLC.
Insilico inked AI drug discovery deal with Takeda Pharmaceutical worth up to $600M. Nippon Shinyaku secured exclusive worldwide rights to develop and commercialize EXG-7001 for DMD from Elixirgen Therapeutics.
Otsuka’s Voyxact demonstrated significant stabilization of kidney function, with evidence of improvement over two years in Phase 3 trial. EMA recommended to pull CSL’s Tavneos from sale in the EU.


APAC Healthcare Weekly (July 5) – CSPC, Abbisko, Insilico, Takeda, Nippon Shinyaku, Otsuka, CSL

South Korea

Daewoong Pharmaceutical Co., Ltd. develops various kinds of medical drugs and vitamin supplements.  The Company's medical drugs are used in areas, such as cardiology, dermatology, anti-biotic, and many other medical areas.  Dae Woong's over-the-counter products include smoking deterrents, vitamins, and minerals.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Daewoong Pharmaceutical Co (069620 KS)

Primer: Daewoong Pharmaceutical Co (069620 KS) - Aug 2026

Daewoong's growth is propelled by the successful global expansion of its key products, the botulinum toxin Nabota and the GERD treatment...

αSK Primers

HK Inno.N (195940 KS): Modest Show In 1Q26; All Eyes on Maiden US Approval; Strengthening Pipeline

HK inno reports 1Q26 result, with key parameters showing improvement compared to year-ago period. The company is expected to maintain momentum,...

Tina Banerjee

Daewoong Pharmaceutical (069620 KS/Buy)Compelling Valuation

Our valuation represents the sum of the firm’s operating value (W2.5tr) and the value of its stake in HanAll Biopharma (W369.9bn), minus net debt...

Mirae Asset Securities

APAC Healthcare Weekly (August 2) – CSPC, Hengrui, Otsuka, Nippon Shinyaku, PharmaEssnetia, Cipla

Hengrui got NMPA approval for long-acting insulin. FDA approves Otsuka’s new CNS drug. Pharmaessentia announced positive topline result from Phase...

Tina Banerjee

APAC Healthcare Weekly (July 5) – CSPC, Abbisko, Insilico, Takeda, Nippon Shinyaku, Otsuka, CSL

CSPC, Insilico, and Abiisko inked outlicensing deals with international companies. Nippon Shinyaku inlicenses DMD drug candidate. EMA recommends to...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Primer: Daewoong Pharmaceutical Co (069620 KS) - Aug 2026

Daewoong's growth is propelled by the successful global expansion of its key products, the botulinum toxin Nabota and the GERD treatment...

αSK Primers

HK Inno.N (195940 KS): Modest Show In 1Q26; All Eyes on Maiden US Approval; Strengthening Pipeline

​HK inno reports 1Q26 result, with key parameters showing improvement compared to year-ago period. The company is expected to maintain momentum,...

Tina Banerjee

Daewoong Pharmaceutical (069620 KS/Buy)Compelling Valuation

Our valuation represents the sum of the firm’s operating value (W2.5tr) and the value of its stake in HanAll Biopharma (W369.9bn), minus net debt...

Mirae Asset Securities

APAC Healthcare Weekly (August 2) – CSPC, Hengrui, Otsuka, Nippon Shinyaku, PharmaEssnetia, Cipla

Hengrui got NMPA approval for long-acting insulin. FDA approves Otsuka’s new CNS drug. Pharmaessentia announced positive topline result from Phase...

Tina Banerjee

APAC Healthcare Weekly (July 5) – CSPC, Abbisko, Insilico, Takeda, Nippon Shinyaku, Otsuka, CSL

CSPC, Insilico, and Abiisko inked outlicensing deals with international companies. Nippon Shinyaku inlicenses DMD drug candidate. EMA recommends to...

Tina Banerjee

HK inno reports 1Q26 result, with key parameters showing improvement compared to year-ago period. The company is expected to maintain momentum,...